97 related articles for article (PubMed ID: 10940505)
1. p53 gene mutations in Bowen's disease in Koreans: clustering in exon 5 and multiple mutations.
Lee HJ; Kim JS; Ha SJ; Roh KY; Seo EJ; Park WS; Lee JY; Park KS; Kim JW
Cancer Lett; 2000 Sep; 158(1):27-33. PubMed ID: 10940505
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation spectrum in Japanese Bowen's disease suggests a role for mutagens other than ultraviolet light.
Takata M; Rehman I; Rees JL
Int J Cancer; 1997 May; 71(3):370-2. PubMed ID: 9139870
[TBL] [Abstract][Full Text] [Related]
3. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
Hsu CH; Yang SA; Wang JY; Yu HS; Lin SR
Br J Cancer; 1999 Jun; 80(7):1080-6. PubMed ID: 10362120
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin.
Saridaki Z; Liloglou T; Zafiropoulos A; Koumantaki E; Zoras O; Spandidos DA
Br J Dermatol; 2003 Apr; 148(4):638-48. PubMed ID: 12752119
[TBL] [Abstract][Full Text] [Related]
5. The relation between p53 mutation and p53 immunostaining in non-melanoma skin cancer.
Campbell C; Quinn AG; Angus B; Rees JL
Br J Dermatol; 1993 Sep; 129(3):235-41. PubMed ID: 8286219
[TBL] [Abstract][Full Text] [Related]
6. [The tumor suppressor gene p53 and its significance for dermatology].
Lübbe J; Kleihues P; Burg G
Hautarzt; 1994 Nov; 45(11):741-5. PubMed ID: 7822196
[TBL] [Abstract][Full Text] [Related]
7. Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations.
Hsieh LL; Chen HJ; Hsieh JT; Jee SH; Chen GS; Chen CJ
Cancer Lett; 1994 Oct; 86(1):59-65. PubMed ID: 7954356
[TBL] [Abstract][Full Text] [Related]
8. Absence of p53 mutations in benign and pre-malignant male genital lesions with over-expressed p53 protein.
Castrén K; Vähäkangas K; Heikkinen E; Ranki A
Int J Cancer; 1998 Aug; 77(5):674-8. PubMed ID: 9688297
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin.
Campbell C; Quinn AG; Ro YS; Angus B; Rees JL
J Invest Dermatol; 1993 Jun; 100(6):746-8. PubMed ID: 8496613
[TBL] [Abstract][Full Text] [Related]
10. Germ line TP53 mutation in a patient with multiple Bowen's disease.
Hatta N; Hatta Y
J Dermatol; 2019 Jun; 46(6):e198-e200. PubMed ID: 30592087
[No Abstract] [Full Text] [Related]
11. p53 expression in Bowen's disease and in microinvasive squamous cell carcinoma of the skin.
Hughes JH; Robinson RA
Mod Pathol; 1995 Jun; 8(5):526-9. PubMed ID: 7675772
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutations in human epithelial skin cancers.
Molès JP; Moyret C; Guillot B; Jeanteur P; Guilhou JJ; Theillet C; Basset-Sèguin N
Oncogene; 1993 Mar; 8(3):583-8. PubMed ID: 8437842
[TBL] [Abstract][Full Text] [Related]
13. Infrequent p53 mutations in arsenic-related skin lesions.
Castrén K; Ranki A; Welsh JA; Vähäkangas KH
Oncol Res; 1998; 10(9):475-82. PubMed ID: 10223623
[TBL] [Abstract][Full Text] [Related]
14. High frequency of DNA aneuploidy detected by DNA flow cytometry in Bowen's disease.
Kawara S; Takata M; Takehara K
J Dermatol Sci; 1999 Sep; 21(1):23-6. PubMed ID: 10468188
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53, p21(Waf1/Cip1) and TGF-beta(3) immunohistochemical staining in Bowen's disease.
Kawakami T; Soma Y; Mizoguchi M; Saito R
Dermatology; 2001; 202(1):9-15. PubMed ID: 11244221
[TBL] [Abstract][Full Text] [Related]
16. Significance of mitotic cells or clumping cells in p53 immunopositivity of Bowen's disease.
Ura H; Nashiro K; Kikuchi K; Imakado S; Matsukawa A; Furue M
Dermatology; 1997; 194(1):87-8. PubMed ID: 9031804
[No Abstract] [Full Text] [Related]
17. Subclonal Evolution of Cancer-Related Gene Mutations in p53 Immunopositive Patches in Human Skin.
Albibas AA; Rose-Zerilli MJJ; Lai C; Pengelly RJ; Lockett GA; Theaker J; Ennis S; Holloway JW; Healy E
J Invest Dermatol; 2018 Jan; 138(1):189-198. PubMed ID: 28844940
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of p2lWaf1/Cip1 immunohistochemical staining in Bowen's disease, but not in disseminated superficial porokeratosis.
Kawakami T; Saito R; Takahashi K
Br J Dermatol; 1999 Oct; 141(4):647-51. PubMed ID: 10583111
[TBL] [Abstract][Full Text] [Related]
19. Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations.
Correa GT; Bernardes VF; de Sousa SF; Diniz MG; Salles JM; Souza RP; De-Paula AM; Gomez RS; Gomes CC
Tumour Biol; 2015 Nov; 36(11):9059-66. PubMed ID: 26084614
[TBL] [Abstract][Full Text] [Related]
20. Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.
Gomes CC; Diniz MG; Orsine LA; Duarte AP; Fonseca-Silva T; Conn BI; De Marco L; Pereira CM; Gomez RS
PLoS One; 2012; 7(7):e41261. PubMed ID: 22829934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
